From the Research
The normal level of Anti-Mullerian Hormone (AMH) in women of reproductive age is typically considered to be between 1.0 to 4.0 ng/mL, with levels below 1 ng/mL associated with a reduced chance of conception, as indicated by the most recent study in 2024 1.
Key Points to Consider
- AMH levels naturally decline with age, peaking in the early to mid-20s and decreasing until menopause.
- Higher AMH values generally indicate a larger pool of remaining follicles, reflecting a woman's ovarian reserve.
- Conditions like polycystic ovary syndrome (PCOS) can affect AMH levels, often causing elevated levels (>5 ng/mL), while diminished ovarian reserve may show lower levels (<1.0 ng/mL).
- AMH testing is most useful when interpreted alongside other fertility markers such as follicle-stimulating hormone (FSH), antral follicle count, and age.
- The test can be performed at any time during the menstrual cycle, as AMH levels remain relatively stable throughout, as supported by previous studies 2, 3, 4, 5.
Clinical Implications
- Low AMH levels (<1 ng/mL) are independently associated with a modest but significant reduction in the chance of conception, as found in the 2024 study 1.
- The inclusion of AMH in fertility assessments can improve the prediction of conception probability and time to pregnancy.
- Clinicians should consider AMH levels in the context of other fertility markers and the individual's overall reproductive health, rather than relying solely on AMH as a predictor of fertility.